Cargando…

Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study

Introduction: Up to 27% of individuals undergoing subthalamic nucleus deep brain stimulation (STN-DBS) have a genetic form of Parkinson's disease (PD). Glucocerebrosidase (GBA) mutation carriers, compared to sporadic PD, present with a more aggressive disease, less asymmetry, and fare worse on...

Descripción completa

Detalles Bibliográficos
Autores principales: David, Fabian J., Munoz, Miranda J., Shils, Jay L., Pauciulo, Michael W., Hale, Philip T., Nichols, William C., Afshari, Mitra, Sani, Sepehr, Verhagen Metman, Leo, Corcos, Daniel M., Pal, Gian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514636/
https://www.ncbi.nlm.nih.gov/pubmed/34659089
http://dx.doi.org/10.3389/fneur.2021.723476
_version_ 1784583435263672320
author David, Fabian J.
Munoz, Miranda J.
Shils, Jay L.
Pauciulo, Michael W.
Hale, Philip T.
Nichols, William C.
Afshari, Mitra
Sani, Sepehr
Verhagen Metman, Leo
Corcos, Daniel M.
Pal, Gian D.
author_facet David, Fabian J.
Munoz, Miranda J.
Shils, Jay L.
Pauciulo, Michael W.
Hale, Philip T.
Nichols, William C.
Afshari, Mitra
Sani, Sepehr
Verhagen Metman, Leo
Corcos, Daniel M.
Pal, Gian D.
author_sort David, Fabian J.
collection PubMed
description Introduction: Up to 27% of individuals undergoing subthalamic nucleus deep brain stimulation (STN-DBS) have a genetic form of Parkinson's disease (PD). Glucocerebrosidase (GBA) mutation carriers, compared to sporadic PD, present with a more aggressive disease, less asymmetry, and fare worse on cognitive outcomes with STN-DBS. Evaluating STN intra-operative local field potentials provide the opportunity to assess and compare symmetry between GBA and non-GBA mutation carriers with PD; thus, providing insight into genotype and STN physiology, and eligibility for and programming of STN-DBS. The purpose of this pilot study was to test differences in left and right STN resting state beta power in non-GBA and GBA mutation carriers with PD. Materials and Methods: STN (left and right) resting state local field potentials were recorded intraoperatively from 4 GBA and 5 non-GBA patients with PD while off medication. Peak beta power expressed as a ratio to total beta power (peak beta ratio) was compared between STN hemispheres and groups while co-varying for age, age of disease onset, and disease severity. Results: Peak beta ratio was significantly different between the left and the right STN for the GBA group (p < 0.01) but not the non-GBA group (p = 0.56) after co-varying for age, age of disease onset, and disease severity. Discussion: Peak beta ratio in GBA mutation carriers was more asymmetric compared with non-mutation carriers and this corresponded with the degree of clinical asymmetry as measured by rating scales. This finding suggests that GBA mutation carriers have a physiologic signature that is distinct from that found in sporadic PD.
format Online
Article
Text
id pubmed-8514636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85146362021-10-15 Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study David, Fabian J. Munoz, Miranda J. Shils, Jay L. Pauciulo, Michael W. Hale, Philip T. Nichols, William C. Afshari, Mitra Sani, Sepehr Verhagen Metman, Leo Corcos, Daniel M. Pal, Gian D. Front Neurol Neurology Introduction: Up to 27% of individuals undergoing subthalamic nucleus deep brain stimulation (STN-DBS) have a genetic form of Parkinson's disease (PD). Glucocerebrosidase (GBA) mutation carriers, compared to sporadic PD, present with a more aggressive disease, less asymmetry, and fare worse on cognitive outcomes with STN-DBS. Evaluating STN intra-operative local field potentials provide the opportunity to assess and compare symmetry between GBA and non-GBA mutation carriers with PD; thus, providing insight into genotype and STN physiology, and eligibility for and programming of STN-DBS. The purpose of this pilot study was to test differences in left and right STN resting state beta power in non-GBA and GBA mutation carriers with PD. Materials and Methods: STN (left and right) resting state local field potentials were recorded intraoperatively from 4 GBA and 5 non-GBA patients with PD while off medication. Peak beta power expressed as a ratio to total beta power (peak beta ratio) was compared between STN hemispheres and groups while co-varying for age, age of disease onset, and disease severity. Results: Peak beta ratio was significantly different between the left and the right STN for the GBA group (p < 0.01) but not the non-GBA group (p = 0.56) after co-varying for age, age of disease onset, and disease severity. Discussion: Peak beta ratio in GBA mutation carriers was more asymmetric compared with non-mutation carriers and this corresponded with the degree of clinical asymmetry as measured by rating scales. This finding suggests that GBA mutation carriers have a physiologic signature that is distinct from that found in sporadic PD. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514636/ /pubmed/34659089 http://dx.doi.org/10.3389/fneur.2021.723476 Text en Copyright © 2021 David, Munoz, Shils, Pauciulo, Hale, Nichols, Afshari, Sani, Verhagen Metman, Corcos and Pal. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
David, Fabian J.
Munoz, Miranda J.
Shils, Jay L.
Pauciulo, Michael W.
Hale, Philip T.
Nichols, William C.
Afshari, Mitra
Sani, Sepehr
Verhagen Metman, Leo
Corcos, Daniel M.
Pal, Gian D.
Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title_full Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title_fullStr Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title_full_unstemmed Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title_short Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
title_sort subthalamic peak beta ratio is asymmetric in glucocerebrosidase mutation carriers with parkinson's disease: a pilot study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514636/
https://www.ncbi.nlm.nih.gov/pubmed/34659089
http://dx.doi.org/10.3389/fneur.2021.723476
work_keys_str_mv AT davidfabianj subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT munozmirandaj subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT shilsjayl subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT pauciulomichaelw subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT halephilipt subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT nicholswilliamc subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT afsharimitra subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT sanisepehr subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT verhagenmetmanleo subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT corcosdanielm subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy
AT palgiand subthalamicpeakbetaratioisasymmetricinglucocerebrosidasemutationcarrierswithparkinsonsdiseaseapilotstudy